J&J планирует упростить доступность "Sirturo" в развивающихся странах

Johnson & Johnson (JNJ) is taking steps to ensure Sirturo, its medicine for people with drug-resistant tuberculosis, is available and properly administered in 130 developing countries across the globe.

The tablet was approved by the U.S. Food and Drug Administration in 2012 as the first new medicine in 40 years to treat the contagious lung infection. It’s recommended by the World Health Organization for use in combination with other drugs to treat those most in danger from the disease. Yet it’s still not approved or affordable in most countries.

J&J agreed to sell the medicine to the Stop TB Partnership as part of a collaboration that will ensure its proper use, said Paul Stoffels, the New Brunswick, New Jersey-based company’s chief scientific officer and worldwide chairman of pharmaceuticals. The deal with the Stichting International Dispensary, which buys medicines on behalf of the WHO, hospitals and governments across the developing world, will ensure the medicine reaches people who need it even in countries where it’s not approved, he said.

“This is one of the most reliable suppliers for tuberculosis drugs and many other medicines to the developing world,” Stoffels said in a telephone interview. “They can, on an exception basis, sort the medicine for people who need it.”

J&J also is pursuing approval of the medicine in many of the countries, though it may take several years to gain clearance. The medicine will be available sooner with tiered pricing in different countries, with the Stop TB Partnership’s global drug facility getting drugs through the Stichting group.